Boxer Capital’s Akero Therapeutics AKRO Stock Holding History

Boxer Capital’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,676,733	Closed	-$48.1M	–	1
2024 Q3	$48.1M	Hold	1,676,733	–	–	2.36%	14
2024 Q2	$39.3M	Hold	1,676,733	–	–	2.07%	15
2024 Q1	$42.4M	Hold	1,676,733	–	–	2.09%	15
2023 Q4	$39.2M	Hold	1,676,733	–	–	1.95%	18
2023 Q3	$84.8M	Hold	1,676,733	–	–	4.51%	5
2023 Q2	$78.3M	Buy	1,676,733 +845,238	+102%	+$38.7M	3.63%	7
2023 Q1	$31.8M	Hold	831,495	–	–	1.56%	18
2022 Q4	$45.6M	Hold	831,495	–	–	2.4%	12
2022 Q3	$28.3M	Hold	831,495	–	–	1.59%	23
2022 Q2	$7.86M	Hold	831,495	–	–	0.5%	44
2022 Q1	$11.8M	Hold	831,495	–	–	0.61%	40
2021 Q4	$17.6M	Hold	831,495	–	–	0.68%	34
2021 Q3	$18.6M	Hold	831,495	–	–	0.65%	45
2021 Q2	$20.6M	Hold	831,495	–	–	0.73%	42
2021 Q1	$24.1M	Hold	831,495	–	–	0.82%	37
2020 Q4	$21.5M	Hold	831,495	–	–	0.69%	41
2020 Q3	$25.6M	Buy	831,495 +415,000	+100%	+$14.5M	0.88%	32
2020 Q2	$10.4M	Hold	416,495	–	–	0.46%	46
2020 Q1	$8.83M	Sell	416,495 -66,000	-14%	-$1.42M	0.6%	39
2019 Q4	$10.7M	Hold	482,495	–	–	0.61%	38
2019 Q3	$11M	Buy	482,495 +85,800	+22%	+$2M	0.8%	30
2019 Q2	$7.6M	Buy	+396,695	New	+$7.52M	0.65%	29

Other funds holding AKRO

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Boxer Capital's AKRO Position: Q4 2024 in Review

Boxer Capital sold out of Akero Therapeutics (AKRO) in Q4 2024, closing a stake of 1,676,733 shares — an estimated $48.1M sold.

Boxer Capital first reported a position in AKRO in Q2 2019 and held it in 22 quarters. The position peaked at $84.8M in Q3 2023. 191 funds tracked by Wall St. Rank hold AKRO as of Q4 2024.

Boxer Capital reported no remaining Akero Therapeutics position as of Q4 2024 after selling out during the quarter.
Boxer Capital sold 1,676,733 Akero Therapeutics shares in Q4 2024, an estimated $48.1M.
Boxer Capital first reported a position in Akero Therapeutics in Q2 2019 and held it in 22 quarters.
Boxer Capital's Akero Therapeutics position peaked at $84.8M in Q3 2023.
191 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.